Main Menu

Research projects

Professor Emma Hall, ICR-CTSU Urology and Head and Neck trials team

The Cancer Research UK-funded Clinical Trials & Statistics Unit (ICR-CTSU) provides the scientific leadership and operational management to develop, conduct and report high quality, innovative randomised trials, with integrated translational and psychosocial research. 

The aims of the research are to continue to develop, conduct and report high quality trials, and associated research, of scientific importance and which will impact directly on clinical practice within the NHS and internationally. 

Professor Emma Hall currently leads on the following Clinical Trials:

Urological Cancer Clinical Trials

A-PREDICT

Phase II study of axitinib in patients with metastatic renal cell cancer unsuitable for nephrectomy. 

BC2001

A randomised phase III study of radiotherapy with and without synchronous chemotherapy in muscle invasive bladder cancer.

BOXIT

This trial is a randomised phase III multi-centre double-blind placebo-controlled clinical trial. The primary objective is to determine if the addition of the oral COX-2 inhibitor celecoxib to standard therapy is more effective in terms of disease recurrence at 3 years compared to standard therapy alone for the treatment of superficial TCC of the bladder in intermediate and high risk patients.

CALIBER

Phase II randomised feasibility study of chemoresection and surgical management in low risk non muscle invasive bladder cancer. 

CHHiP

Conventional or Hypofractionated High Dose Intensity Modulated Radiotherapy for Prostate Cancer.

HYBRID

Randomised controlled trial of laparoscopic, open and robot assisted prostatectomy as treatment for organ confined prostate cancer.

InPACT

International penile advanced cancer trial  - an International Rare Cancers Initiative study.

Intercontinental

An international phase III randomised trial comparing intermittent versus continuous androgen suppression for patients with prostate-specific-antigen progression in the clinical absence of distant metastases following radiotherapy for prostate cancer.

LopeRA

A randomised controlled trial of laparoscopic, open and robot assisted prostatectomy as treatment for organ-confined prostate cancer

PACE

International randomised study of laparoscopic prostatectomy vs stereotactic body radiotherapy (SBRT) and conventional radiotherapy vs SBRT for early stage organ-confined prostate cancer.

Penile TPF

A Phase II Trial of docetaxel, cisplatin & 5-fluorouracil chemotherapy (TPF) in locally advanced and metastatic carcinoma of the penis.

PIVOTAL

A randomised phase II trial of Prostate and pelvIs versus prOstaTe Alone treatment for Locally advanced prostate cancer.

POUT

Phase III randomised trial of peri-operative chemotherapy versus surveillance in upper tract urothelial cancer.

PROMPTS

Prospective randomised phase III study of observation versus screening MRI and pre-emptive treatment in castrate resistant prostate cancer patients with spinal metastasis.

ProSTART

A Pilot Study for a Phase III Clinical Trial in Patients with Favourable Risk Prostate Cancer Comparing Active Surveillance Therapy Against Radical Treatment.

RAIDER

Randomised phase II trial of adaptive image guided standard or dose escalated tumour boost radiotherapy in the treatment of transitional cell carcinoma of the bladder.

RE-AKT

Randomised phase II study of enzalutamide (MDV3100) in combination with AZD5363 in patients with metastatic castration resistant prostate cancer.

REASURE

Phase II open label study of biomarkers to assess response in patients with metastatic castration-resistant prostate cancer treated with radium-223.

SPARE

Randomised trial of Selective bladder Preservation Against Radical Excision (cystectomy) in muscle invasive T2/T3 transitional cell carcinoma of the bladder - feasibility study.

TIGER

A randomised phase III trial comparing conventional dose chemotherapy using paclitaxel, ifosfamide and cisplatin (TIP) with high dose chemotherapy using mobilising paclitaxel plus ifosfamide followed by high dose carboplatin and etoposide (TI-CE) as first treatment in relapsed or refractory germ cell tumours.

TOPARP

Phase II trial of olaparib in patients with advanced castration resistant prostate cancer.

VinCaP

Phase II trial of vinflunine chemotherapy in locally advanced and metastatic carcinoma of the penis.

111 Trial

The 111 trial is a single group trial evaluating one cycle of adjuvant BEP chemotherapy in high risk, stage 1 non-seminomatous germ cell tumours of the testis (NSGCTT).

 

Head & Neck Cancer Clinical Trials

ART DECO

A phase III multi-centre randomised controlled trial to determine the potential of dose escalated IMRT to improve locoregional failure free rate (LRFFR) and laryngeal preservation in patients with locally advanced laryngeal and hypopharyngeal cancers, without increasing the incidence of severe acute and late toxicities to unacceptable levels.

COSTAR

COchlear Sparing Therapy And conventional Radiation - a phase III multi-centre randomised controlled trial designed to demonstrate a difference in the proportion of patients suffering sensori-neural hearing loss of at least 10dB in bone conduction at 4000 Hz.

DARS

A phase III randomised multicentre study of dysphagia optimised intensity modulated radiotherapy (Do-IMRT) versus standard intensity modulated radiotherapy (S-IMRT) in head and neck cancer.

EORTC1206-HNCG

A phase III randomised multicentre study of dysphagia optimised intensity modulated radiotherapy (Do-IMRT) versus standard intensity modulated radiotherapy (S-IMRT) in head and neck cancer.

PARSPORT

A Phase III multi-centre randomised controlled trial of parotid sparing IMRT in patients with head and neck cancer.

We use cookies to ensure that we give you the best experience on our website. By continuing to use this website, you are agreeing to our use of cookies on your device as described in our cookie policy. You can change your cookie settings at any time but parts of our site will not function correctly without them.